Osimertinib, as an irreversible EGFR-TKI, does influence the treatment strategy for T790M-mutant NSCLC patients with approximately 60% objective response rate and 9 months' duration of progression-free survival [9–11]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.